Identification of Key Pathways and Genes in the Orai2 Mediated Classical and Mesenchymal Subtype of Glioblastoma by Bioinformatic Analyses. (20th October 2019)
- Record Type:
- Journal Article
- Title:
- Identification of Key Pathways and Genes in the Orai2 Mediated Classical and Mesenchymal Subtype of Glioblastoma by Bioinformatic Analyses. (20th October 2019)
- Main Title:
- Identification of Key Pathways and Genes in the Orai2 Mediated Classical and Mesenchymal Subtype of Glioblastoma by Bioinformatic Analyses
- Authors:
- Yuan, Feng
Yi, Li
Hai, Long
Wang, Yingshuai
Yang, Yihan
Li, Tao
Tong, Luqing
Ma, Haiwen
Liu, Peidong
Ming, Haolang
Ren, Bingcheng
Yu, Shengping
Lin, Yu
Yang, Xuejun - Other Names:
- Agrogiannis George Academic Editor.
- Abstract:
- Abstract : Background . Ca 2+ release-activated Ca 2+ channels (CRAC) are the main Ca 2+ entry pathway regulating intracellular Ca 2+ concentration in a variety of cancer types. Orai2 is the main pore-forming subunit of CRAC channels in central neurons. To explore the role of Orai2 in glioblastoma (GBM), we investigated the key pathways and genes in Orai2-mediated GBM by bioinformatic analyses. Methods . Via The Cancer Genome Atlas (TCGA), French, Sun, and Gene Expression Omnibus (GEO) (GDS3885) datasets, we collected 1231 cases with RNA-seq data and analyzed the functional annotation of Orai2 by gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. Univariate and multivariate survival analyses were applied to 823 patients with survival data. Results . We discovered that Orai2 was markedly upregulated in GBM compared to normal brain samples and lower-grade gliomas (LGG). Survival analysis found that higher expression of Orai2 was independently associated with a worse prognosis of patients with the classical and mesenchymal subtypes of GBM. Simultaneously, Orai2 expression was higher in tumors of the classical and mesenchymal subtypes than other subtypes and was significantly correlated with classical- and mesenchymal-related genes. GO and KEGG pathway analysis revealed that genes significantly correlated with Orai2 were involved in the JNK pathway. Through screening transcriptomic data, we found a strong association between Orai2 andAbstract : Background . Ca 2+ release-activated Ca 2+ channels (CRAC) are the main Ca 2+ entry pathway regulating intracellular Ca 2+ concentration in a variety of cancer types. Orai2 is the main pore-forming subunit of CRAC channels in central neurons. To explore the role of Orai2 in glioblastoma (GBM), we investigated the key pathways and genes in Orai2-mediated GBM by bioinformatic analyses. Methods . Via The Cancer Genome Atlas (TCGA), French, Sun, and Gene Expression Omnibus (GEO) (GDS3885) datasets, we collected 1231 cases with RNA-seq data and analyzed the functional annotation of Orai2 by gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. Univariate and multivariate survival analyses were applied to 823 patients with survival data. Results . We discovered that Orai2 was markedly upregulated in GBM compared to normal brain samples and lower-grade gliomas (LGG). Survival analysis found that higher expression of Orai2 was independently associated with a worse prognosis of patients with the classical and mesenchymal subtypes of GBM. Simultaneously, Orai2 expression was higher in tumors of the classical and mesenchymal subtypes than other subtypes and was significantly correlated with classical- and mesenchymal-related genes. GO and KEGG pathway analysis revealed that genes significantly correlated with Orai2 were involved in the JNK pathway. Through screening transcriptomic data, we found a strong association between Orai2 and apoptosis, stemness, and an epithelial-mesenchymal transition- (EMT-) like phenotype. Conclusion . As a prognostic factor, Orai2 is obviously activated in the classical and mesenchymal subtypes of GBM and promotes glioma cell self-renewal, apoptosis, and EMT-like by the JNK pathway. These findings indicate that Orai2 could be a candidate prognostic and therapeutic target, especially for the classical and mesenchymal subtypes of GBM. … (more)
- Is Part Of:
- Disease markers. Volume 2019(2019)
- Journal:
- Disease markers
- Issue:
- Volume 2019(2019)
- Issue Display:
- Volume 2019, Issue 2019 (2019)
- Year:
- 2019
- Volume:
- 2019
- Issue:
- 2019
- Issue Sort Value:
- 2019-2019-2019-0000
- Page Start:
- Page End:
- Publication Date:
- 2019-10-20
- Subjects:
- Diagnosis -- Periodicals
Biochemical markers -- Periodicals
Pathology -- Periodicals
616 - Journal URLs:
- https://www.hindawi.com/journals/dm/ ↗
- DOI:
- 10.1155/2019/7049294 ↗
- Languages:
- English
- ISSNs:
- 0278-0240
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library HMNTS - ELD Digital store
- Ingest File:
- 12107.xml